SciELO - Scientific Electronic Library Online

 
vol.99 número11 índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

    Links relacionados

    • Em processo de indexaçãoCitado por Google
    • Em processo de indexaçãoSimilares em Google

    Compartilhar


    SAMJ: South African Medical Journal

    versão On-line ISSN 2078-5135versão impressa ISSN 0256-9574

    SAMJ, S. Afr. med. j. vol.99 no.11 Pretoria Nov. 2009

     

    CORRESPONDENCE

     

    Linezolid dosing for staphylococcal pneumonia in children

     

     

    To the Editor: We have noticed that the dose recommendation for linezolid use in our Guideline for VAP in children, recently published in the SAMJ,1 is incorrect.

    Results from studies in paediatric patients have demonstrated that there are age-related differences in the pharmacokinetic parameters of linezolid.2 Children <12 years old have a smaller area under the Cmax curve (AUC), a faster clearance and a shorter elimination half-life than adults. Newborn infants have clearance values similar to those of adults. However, clearance increases rather markedly during the first week of life, to values 2 - 3 times in excess of those observed in older children and adults. The clearance of linezolid declines gradually in young children, becoming similar to that of adults by adolescence. After the age of 12 years, the pharmacokinetic parameters for linezolid are not significantly different from those of adults. The age-related changes in linezolid pharmacokinetics have implications for the appropriate dosing of the drug. These findings support the need for a shorter dosing interval in infants and young children to provide adequate drug exposure. In particular, more frequent administration will increase the AUC and plasma trough concentrations. This is important because the AUC:MIC ratio and the time above the minimum inhibitory concentration (MIC) are important determinants of linezolid efficacy against Gram-positive pathogens.

    The recommended dosing guidelines for linezolid according to age are that, for most indications, children <12 years old should receive linezolid 10 mg/kg every 8 hours. The only exception to this is the treatment of uncomplicated skin and skin structure infections, for which the 8-hourly schedule is recommended only for children <5 years old. Because of the lower systemic clearance values and higher AUC values in preterm infants <7 days old, a dosing regimen of 10 mg/kg every 12 h should be initiated for these neonates. However, a 10 mg/kg every 8 h regimen should be considered for those with inadequate clinical response. In addition, the dosage should be changed to 10 mg/kg every 8 h for all neonates by the 7th day of life.

    We trust this clarifies the issue.

    Robin Green

    Division of Paediatric Pulmonology and Intensive Care
    Department of Paediatrics and Child Health
    University of Pretoria and
    Steve Biko Academic Hospital
    Pretoria
    robin.green@up.ac.za

    Brenda Morrow

    Andrew Argent

    Argent Division of Paediatric Critical Care and Children's Heart Disease
    School of Child and Adolescent Health
    University of Cape Town and
    Red Cross War Memorial Children's Hospital
    Cape Town

    Prakash Jeena

    Division of Paediatric Pulmonology and Intensive Care
    Department of Paediatrics and Child Health
    University of KwaZulu-Natal and
    Inkosi Albert Luthuli Hospital
    Durban

     

    1. Morrow BM, Argent AC, Jeena PM, Green RJ. Guideline for the diagnosis, prevention and treatment of paediatric ventilator-associated pneumonia. S Afr Med J 2009; 99: 253-267.         [ Links ]

    2. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003; 22: S153-157.         [ Links ]